<DOC>
	<DOCNO>NCT02202993</DOCNO>
	<brief_summary>This dose-escalation study ass safety determine maximum tolerate dose ( MTD ) mibefradil dihydrochloride , partially selective T-type calcium channel blocker , combine hypofractionated radiation therapy ( RT ) subject recurrent glioblastoma multiforme ( GBM ) .</brief_summary>
	<brief_title>TAU-2014-1 : Mibefradil Hypofractionated Re-Irradiation Therapy Recurrent GBM</brief_title>
	<detailed_description>Patients receive mibefradil dihydrochloride , dose escalate 150mg/day maximum tolerate dose ( MTD ) determine , dose 350 mg/day reach use standard 3 + 3 design . Mibefradil dihydrochloride dose orally 4 divided dos per day 17 consecutive day MTD . The MTD determine accord dose-limiting toxicity ( DLTs ) grade use Common Terminology Criteria Adverse Events version 4.0 . Radiation therapy ( RT ) consist 5 fraction 600 centigray ( cGy ) , deliver 2 consecutive week total dose 3,000 cGy , use stereotactic , intensity-modulated radiation therapy ( IMRT ) . The primary endpoint study determine MTD mibefradil dihydrochloride give concurrent hypofractionated RT . Secondary tertiary endpoint include evaluate efficacy mibefradil dihydrochloride RT term progression-free survival ( PFS ) overall survival ( OS ) , perform translational research resect tumor tissue .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Mibefradil</mesh_term>
	<criteria>Sign write informed consent . Histologically proven glioblastoma multiforme ( GBM ) progressive recurrent follow standard radiation therapy ( RT ) temozolomide ( i.e. , least `` biopsyproven '' recurrent disease ) . Previous salvage therapy first recurrence permit . Measurable contrastenhancing progressive recurrent GBM ( single multiple lesion ) MRI image interval great equal 6 month recurrence completion prior radiotherapy . Patients pass interval least 6 month may still eligible meet follow criterion : convincing histologic evidence disease recurrence think predominantly represent radionecrosis , standard focal external beam radiation therapy ( EBRT ) treatment acceptable dos tumor normal tissue suggest reirradiation feasible . Prior history standard dose focal RT 60 Gy 30 fraction 59.4 Gy 1.8 Gy fraction , equivalent low dos . Patients receive prior treatment nonstandard RT dose fractionation scheme still eligible , provide receive single course RT . However , subject treat interstitial brachytherapy singlefraction stereotactic radiosurgery eligible trial . Karnofsky performance status ≥60 % Clinical laboratory : absolute neutrophil count &gt; 1,500/microliter ( mcL ) platelets &gt; 100,000/mcL hemoglobin &gt; 9 g/ dL serum bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; unless due Gilbert 's syndrome ( &lt; 2 time ULN acceptable ) serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; 2.5 time ULN serum Creatinine &lt; 1.5 time ULN Women childbearing potential men must agree use adequate contraception . Women childbearing potential must negative pregnancy test prior treatment . Recovered Common Toxicity Criteria Adverse Effects ( CTCAE ) grade ≤ 2 prior therapy toxicity 30 day since previous treatment brain tumor agent . Stable decrease corticosteroid regimen ( increase 7 day ) prior start treatment . &gt; 18 year age Concurrent malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix , breast , bladder . Subjects prior malignancy must diseasefree ≥ five year . Biopsyconfirmed exclusive radionecrosis initial GBM therapy . Receipt investigational agent anticancer agent within 30 day Serious concurrent infection medical illness , would jeopardize ability subject receive treatment safely . Systolic blood pressure &lt; 100 mm Hg , diastolic &lt; 60 mm Hg . Requirement calcium channel blocker blood pressure control switch antihypertensive alternative mechanism action . Permitted antihypertensive medication include : chlorothiazide , hydrochlorothiazide , atenolol , nadolol , enalapril , lisinopril , eprosartan , irbesartan . Known , active hepatitis . correct QT ( QTc ) interval ≥ 450 millisecond ( mSec ) males ≥470 mSec female . PR interval &gt; 250 mSec male female Highgrade ( second degree ) atriaventricular ( AV ) block persistent sinus bradycardia le 50 beat per minute ( BPM ) . Known HIVpositivity Pregnant and/or lactate woman Antiarrhythmia medication betablockers digoxin . Treatment concurrent enzymeinducing antiepileptic drug ( EIAEDs ) . Treatment unfractionated heparin . Patients take anticoagulant must use warfarin low molecular weight heparin . Treatment specify drug substrates cytochrome 3A4 ( CYP3A4 ) , cytochrome 2D6 ( CYP2D6 ) , cytochrome 1A2 ( CYP1A2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>